文献速递静脉血栓栓塞

AngioVac 抽吸取栓治疗癌症患者右心房血栓安全有效

AngioVac Aspiration Thrombectomy of Right Atrial Thrombus is Safe and Effective in Cancer Patients.
PubMed 文献 · Ann Vasc Surg · 2021-08-23

本研究为单中心回顾性病例对照研究,纳入 2013 年 8 月至 2020 年 7 月接受 AngioVac 抽吸取栓的右心房血栓患者 44 例,其中活动性恶性肿瘤 20 例。肿瘤组 Charlson 共病指数显著更高(P = 0.01),但两组生存率(P = 0.8)和技术成功率(OR 3,95%CI 0.83-10.9)无差异。共发生 9 例并发症,包括 6 例轻微、1 例中度、1 例严重和 1 例死亡。结论认为 AngioVac 抽吸取栓在癌症患者中与无癌症患者同样安全有效。

要点

  • 癌症患者右心房血栓接受 AngioVac 抽吸取栓的技术成功率与无癌症患者无差异。
  • 肿瘤组 Charlson 共病指数显著更高,但生存率与对照组无差异。
  • 总体并发症 9 例,包括 1 例死亡,需权衡获益与风险。

核心结论

  • AngioVac 抽吸取栓治疗右心房血栓在癌症患者中与无癌症患者同样安全有效。

研究设计与样本

  • 单中心回顾性病例对照研究,经机构审查委员会批准,纳入 2013 年 8 月至 2020 年 7 月接受 AngioVac 抽吸取栓的右心房血栓患者 44 例,其中活动性恶性肿瘤 20 例。

主要发现

  • 肿瘤组 Charlson 共病指数显著高于非肿瘤组(P = 0.01)。
  • 肿瘤组与非肿瘤组生存率无差异(P = 0.8)。
  • 技术成功率的比值比为 3(95%CI 0.83-10.9)。
  • 共发生 9 例并发症,包括 6 例轻微、1 例中度、1 例严重和 1 例死亡。

临床怎么用

  • 对于癌症合并右心房血栓患者,AngioVac 抽吸取栓可作为避免更高风险干预的供选方案。

局限性

  • 回顾性单中心设计,样本量有限(44 例),结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to test the hypothesis that endovascular aspiration thrombectomy of right atrial thrombus (RAT) using the AngioVac device is as safe and effective in patients with cancer as those without cancer. BACKGROUND: RAT is a uniquely challenging clinical presentation of venous thromboembolism due to its low incidence and historically high-risk of mortality due to thrombus propagation into the pulmonary arteries. There is a lack of consensus regarding management, particularly in high-risk cancer patients. Endovascular aspiration thrombectomy utilizing the AngioVac device is effective in removal of right atrial thrombus and may be a safer option for patients with cancer in whom avoidance of higher-risk intervention is preferred. METHODS: This was an institutional review board-approved retrospective single-center case control study of patients with RAT who underwent AngioVac aspiration thrombectomy between August 2013 and July 2020. Analysis of patient demographics and clinical characteristics, thrombus-related factors, and operative details was performed. Primary endpoints included survival, safety, and technical success. RESULTS: A total of 44 patients met inclusion criteria, 20 of whom with active malignancy. The oncology group had a significantly higher Charlson comorbidity index (P = 0.01). Comparative outcomes between the oncology and non-oncology group showed no difference in survival (P = 0.8) or technical success (OR 3, 95% CI 0.83-10.9). There were 9 complications, including 6 minor, 1 moderate, 1 severe, and 1 death. CONCLUSIONS: AngioVac aspiration thrombectomy of RAT is as safe and effective in patients with cancer as those without cancer.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Callese TE, O'Brien DP, Wilhalme H, et al. AngioVac Aspiration Thrombectomy of Right Atrial Thrombus is Safe and Effective in Cancer Patients. Ann Vasc Surg. 2021. PMID: 34437971. doi:10.1016/j.avsg.2021.05.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。